Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

330 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
[Immunotherapy of cancer: light at the end of the tunnel?].
Darrasse-Jèze G, Klatzmann D. Darrasse-Jèze G, et al. Med Sci (Paris). 2011 Oct;27(10):795-7. doi: 10.1051/medsci/20112710001. Epub 2011 Oct 21. Med Sci (Paris). 2011. PMID: 22027410 French. No abstract available.
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.
Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, Chaput N, Barrou B, Thioun N, Gattegnio B, Selles F, Six A, Azar N, Lotz JP, Buzyn A, Sibony M, Delcourt A, Boyer O, Herson S, Klatzmann D, Lacave R. Lemoine FM, et al. Int J Oncol. 2009 Sep;35(3):569-81. doi: 10.3892/ijo_00000368. Int J Oncol. 2009. PMID: 19639177 Clinical Trial.
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Hartemann A, et al. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8. Lancet Diabetes Endocrinol. 2013. PMID: 24622415 Clinical Trial.
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy.
Touil S, Rosenzwajg M, Landau DA, Le Corvoisier P, Frédéric C, Klatzmann D, Maury S, Cohen JL. Touil S, et al. Haematologica. 2012 Nov;97(11):1678-85. doi: 10.3324/haematol.2011.056374. Epub 2012 May 11. Haematologica. 2012. PMID: 22581007 Free PMC article. Clinical Trial.
Systems biology in vaccine design.
Six A, Bellier B, Thomas-Vaslin V, Klatzmann D. Six A, et al. Microb Biotechnol. 2012 Mar;5(2):295-304. doi: 10.1111/j.1751-7915.2011.00321.x. Epub 2011 Dec 21. Microb Biotechnol. 2012. PMID: 22189033 Free PMC article. Review.
Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses.
Dérian N, Bellier B, Pham HP, Tsitoura E, Kazazi D, Huret C, Mavromara P, Klatzmann D, Six A. Dérian N, et al. PLoS Comput Biol. 2016 Mar 21;12(3):e1004801. doi: 10.1371/journal.pcbi.1004801. eCollection 2016 Mar. PLoS Comput Biol. 2016. PMID: 26998760 Free PMC article.
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.
Courau T, Nehar-Belaid D, Florez L, Levacher B, Vazquez T, Brimaud F, Bellier B, Klatzmann D. Courau T, et al. JCI Insight. 2016 Jun 16;1(9):e85974. doi: 10.1172/jci.insight.85974. JCI Insight. 2016. PMID: 27699271 Free PMC article.
Regulatory T cells in the treatment of disease.
Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC. Sharabi A, et al. Nat Rev Drug Discov. 2018 Nov;17(11):823-844. doi: 10.1038/nrd.2018.148. Epub 2018 Oct 12. Nat Rev Drug Discov. 2018. PMID: 30310234 Review.
B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P. Rosenzwajg M, et al. Kidney Int. 2017 Jul;92(1):227-237. doi: 10.1016/j.kint.2017.01.012. Epub 2017 Mar 15. Kidney Int. 2017. PMID: 28318628 Clinical Trial.
Regulatory T Cells Orchestrate Similar Immune Evasion of Fetuses and Tumors in Mice.
Nehar-Belaid D, Courau T, Dérian N, Florez L, Ruocco MG, Klatzmann D. Nehar-Belaid D, et al. J Immunol. 2016 Jan 15;196(2):678-90. doi: 10.4049/jimmunol.1501834. Epub 2015 Dec 7. J Immunol. 2016. PMID: 26643476
330 results
Jump to page